SB4 Summary: Right to Try Act

• Creates the "Right to Try Act" allowing terminally ill patients to access investigational drugs, biological products, or devices that have completed phase I clinical trials but lack FDA approval.

• Establishes eligibility requirements including: terminal illness diagnosis, no comparable FDA-approved treatment options, inability to access clinical trials within 100 miles or within one week of application, physician prescription, and written informed consent.

• Permits drug manufacturers to provide investigational treatments without charge or to require patients to pay only actual out-of-pocket manufacturing costs; protects patient heirs from liability for outstanding debts if patient dies during treatment.

• Prohibits licensing boards from revoking or denying renewal of physician, medical professional, or hospital licenses based on recommending, prescribing, or participating in investigational drug treatment.

• Provides civil liability immunity to manufacturers, distributors, prescribers, and others involved in care (except for gross negligence or willful misconduct) and clarifies that Medicaid is not required to cover investigational drugs under this Act.